Roche flags early success for Tecentriq combos, hustles into PhIIIs
After wrapping a pair of early-stage combination studies for melanoma using its PD-L1 checkpoint drug Tecentriq (atezolizumab), Roche now plans to hustle straight into Phase III for each of them as it looks to continue to ramp up its growing cancer franchise in the face of some tough competition from Merck and Bristol-Myers Squibb.
Combining Tecentriq with its MEK inhibitor Cotellic along with the BRAF inhibitor Zelboraf delivered an 83% overall response rate in their Phase Ib, with 3 of 24 — out of 29 total previously untreated patients with BRAF mutation-positive melanoma — seeing complete responses. There were no grade 5 adverse events in the study, but 40% did experience a grade 3 or 4 AE with the triple combo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
